Hydroxycitric acid compounds and capsule liquid delivery

Abstract

A capsule oral delivery system is disclosed. The system includes an outer capsule completely enclosing an inner content, or a hard shell comprised of hydroxypropyl methylcellulose (HPMC) enclosing the content. A liquid formulation forming the inner content of the outer capsule is comprised of a hydroxycitric acid (HCA) salt, water, and glycerol, with the HCA being completely dissolved in the water and glycerol which may be the only components present in the capsule, which may be administered to a patient in a method of treatment to cause weight loss when repeatedly administered.

1 - 19 . (canceled) 
     
     
         20 . A method of treatment, comprising:
 administering to a subject a liquid formulation, comprising:   a salt of hydroxycitric acid (HCA), water, and glycerol, whereby the HCA salt is completely dissolved in the water and glycerol;   wherein the liquid formulation is prepared by mixing glycerol in water wherein the glycerol is present in an amount of about 1 to 3 parts by volume and the water is present in an amount of about 3 to 1 parts by volume to create a solution;   dissolving hydroxycitrate salt in the solution wherein the hydroxycitrate salt is present in a concentration ranging from about 1.1 to 1.7 molar dosage; and   repeating the administering over a period of time.   
     
     
         21 . The method of  claim 20  wherein the hydroxycitrate salt is a stable hydroxycitrate salt selected from a group consisting of sodium, potassium, potassium-magnesium or magnesium hydroxycitrate; double- or triple-metal salts based on the counter ions selected from the group consisting of magnesium, potassium and sodium; and any workable combination thereof. 
     
     
         22 . The method of  claim 21 , wherein the hydroxycitrate salt is a potassium-magnesium salt of (−)-hydroxycitric acid and is present in an amount of 750 mg. 
     
     
         23 . The method of  claim 20 , wherein the liquid formulation contains from 500 mg to 1000mg of the HCA salt and is administered from three times per day to six times per day over a period of weeks. 
     
     
         24 . The method of  claim 20 , wherein the liquid formulation contains 750 mg of HCA salt and is administered to the patient three times per day to six times per day over a period of weeks. 
     
     
         25 . The method of  claim 20 , wherein the liquid formulation contains 750 mg of HCA salt and is administered to the patient three times per day over a period of 6 weeks. 
     
     
         26 . A method of treatment, comprising:
 administering to a subject a capsule with an outer capsule comprised of hydroxypropyl methylcellulose completely enclosing an inner content;   wherein the inner content is liquid formulation comprising a potassium-magnesium salt of hydroxycitric acid (HCA), water, and glycerol, whereby the HCA salt is completely dissolved in the water and glycerol;   wherein the liquid formulation is prepared by mixing glycerol in water wherein the glycerol is present in an amount of about 1 to 3 parts by volume and the water is present in an amount of about 3 to 1 parts by volume to create a solution;   dissolving hydroxycitrate salt in the solution wherein the hydroxycitrate salt is present in a concentration ranging from about 1.1 to 1.7 molar dosage; and   repeating the administering over a period of time.   
     
     
         27 . The method of  claim 26 , wherein the hydroxycitrate salt is a stable hydroxycitrate salt selected from a group consisting of sodium, potassium, potassium-magnesium or magnesium hydroxycitrate; double- or triple-metal salts based on the counter ions selected from the group consisting of magnesium, potassium and sodium; and any workable combination thereof. 
     
     
         28 . The method of  claim 26 , wherein the hydroxycitrate salt is a potassium-magnesium salt of (−)-hydroxycitric acid. 
     
     
         29 . The method of  claim 26 , wherein the liquid formulation contains from 500 mg to 1000 mg of the HCA salt and is administered from three times per day to six times per day over a period of weeks. 
     
     
         30 . The method of  claim 26 , wherein the liquid formulation contains 750 mg of HCA salt and is administered to the patient three times per day to six times per day over a period of weeks. 
     
     
         31 . The method of  claim 26 , wherein the liquid formulation contains 750 mg of HCA salt and is administered to the patient three times per with two capsules administered each time over a period of 6 weeks.